Linezolid in Infants and Children with Severe Gram-Positive Infections: A Viewpoint by Jaime G. Deville

ISSN： 1174-5878

Source： Pediatric Drugs, Vol.5, Iss.6, 2003-01, pp. : 430-431

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Linezolid: In Infants and Children with Severe Gram-Positive Infections

By Lyseng-Williamson K.A. Goa K.L.

Pediatric Drugs, Vol. 5, Iss. 6, 2003-01 ,pp. : 419-429

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Linezolid for Serious Gram-Positive Bacterial Infections

By Falagas Matthew E. Vardakas Konstantinos Z.

Drug Safety, Vol. 31, Iss. 9, 2008-01 ,pp. : 753-768

Adis International

Access to resources Recommend Favorite

Linezolid: A Pharmacoeconomic Review of its Use in Serious Gram-Positive Infections

By Plosker Greg L. Figgitt David P.

PharmacoEconomics, Vol. 23, Iss. 9, 2005-01 ,pp. : 945-964

Adis International

Access to resources Recommend Favorite

Linezolid: A Review of its Use in the Management of Serious Gram-Positive Infections

By Perry C.M. Jarvis B.

Drugs, Vol. 61, Iss. 4, 2001-01 ,pp. : 525-551

Adis International

Access to resources Recommend Favorite

`Synercid' - a novel agent for severe multiresistant Gram-positive infections

Inpharma, Vol. 1, Iss. 1227, 2000-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite